Oncology and Hematology Top Stories of 2012

Letter to Readers |
December 26, 2012

Oncology and Hematology Top Stories of 2012

  1. William J. Gradishar, MD

A perspective on the most important research in the field from the past year

  1. William J. Gradishar, MD

This year, our list of the top 10 Journal Watch Oncology and Hematology stories covers a broad range of topics, including benign and malignant hematology and cancers of the breast, prostate, and gastrointestinal tract. These summaries illustrate our goal of identifying the most clinically relevant journal articles and highlighting their key points, limitations, and implications.

Our top stories for 2012 are:

T-DM1 Prolongs Survival in Advanced HER2-Positive Breast Cancer

Second-Generation Antiandrogen for Advanced Prostate Cancer

Intermittent vs. Continuous Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer

Radical Prostatectomy vs. Observation for Early-Stage Prostate Cancer

Preoperative Chemoradiotherapy Improves Survival in Esophageal Cancer

Longer Imatinib Therapy Effective for Gastrointestinal Stromal Tumors

Tumor Heterogeneity Challenges Targeted Therapy

Maintenance Lenalidomide for Multiple Myeloma

Ruxolitinib Effective for Myelofibrosis

Preventing Thrombosis During Chemotherapy

All best wishes for the New Year,

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.